FDA Approves Unknown Drug — LUPIN

# FDA Approves Lupin's Generic Drug Application Lupin Limited received FDA approval for its abbreviated new drug application (ANDA 214398) on September 16, 2025, expanding the company's generic portfolio and positioning it to capture additional market share in the competitive U.S. generic pharmaceuticals sector. The approval strengthens Lupin's commercial footprint and diversifies its revenue streams in a market increasingly focused on cost-effective treatment alternatives.